MOLECULAR IMAGING CORE
MOLECULAR IMAGING CORE
批准号:
8052118
负责人:
RALPH WEISSLEDER, MD, PHD
金额:
$55.46万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-01-01 至 2011-12-31
关键词:
AcuteAddressAffectAnatomyBiochemistryBioinformaticsBiological MarkersBiologyChinCollaborationsCollagenComplexDevelopmentDrug Delivery SystemsEnzymesErinaceidaeGenesGeneticGlucoseGlutamineGoalsGrowth FactorHousingHybridsImageImage AnalysisImaging TechniquesImaging technologyInvestigationKRAS2 geneLocationLogisticsLuciferasesMEK inhibitionMEKsMagnetic Resonance ImagingMaintenanceMeasuresMetabolismMitochondriaModelingMolecularMonitorMusOnline SystemsOpticsPancreatic Ductal AdenocarcinomaPathway interactionsPerformancePharmaceutical PreparationsPhenforminPhosphotransferasesPhysiologicalPositron-Emission TomographyProtocols documentationQuality ControlRNA InterferenceReactive Oxygen SpeciesReadingReagentResearchResearch InfrastructureResearch PersonnelResolutionResourcesSHH geneScreening procedureServicesSystems BiologyTechnical ExpertiseTechniquesTechnologyTestingTherapeuticTherapeutic EffectTherapeutic InterventionTherapeutic StudiesTracerTreatment EfficacyTumor VolumeValidationWithdrawalXenograft Modelcohortcostdesignglucose metabolismglucose uptakeimaging probein vivoinhibitor/antagonistinnovationnovelpancreatic neoplasmprogramsresearch studyresponsetumor
中文摘要
无创的PDAC发展、维持和治疗效果的纵向成像是P01所有部分的基本方面。核心服务于两个特定目的:a)作为执行和协助所有体内成像实验的高科技核心和智力资源;b)作为创新研究核心,为来自不同项目的高优先级目标开发新的成像协议和试剂。这些项目不仅将使用Core来检测肿瘤的位置和大小,而且重要的是,它还可以监测针对特定途径的药物的反应。例如,K-Ras和PI3K通路的激活开启了葡萄糖摄取和代谢的基因;关闭这些通路的药物通常会在肿瘤缩小之前引起18FDG-PET的急性变化。同样,Myc调控葡萄糖摄取基因,因此影响Myc通路的药物也有望对葡萄糖摄取和代谢产生急性影响。核心有效地利用现有的成像资源,但特别关注PDAC生物学的独特方面和项目中提出的治疗干预措施。具体来说,核心将提供:a) GEMS中用于PDAC成像的所有常规成像技术和协议,b)可临床翻译的技术和成像协议,包括MRI和PET-CT, c)高通量光学筛选能力,d)定量图像分析的技术专业知识,e)在整个联盟中进行图像存档和分发的必要基础设施和专业知识,f)设计专业知识,与项目目标相关的新型成像探针的合成和验证;g)包括住房在内的小鼠队列纵向成像的生理支持和后勤。核心由MGH系统生物学中心的大量基础设施提供支持,其中包括广泛的生物化学工作,计算和定量图像分析,以及基于网络的生物信息学平台(MlPortal),以确保获得成像研究。
英文摘要
Noninvasive, longitudinal imaging of PDAC development, maintenance and therapeutic efficacy is a fundamental aspect for all portions of this P01. The core serves two specific purposes: a) as a high-tech core and intellectual resource to perform and assist with all In vivo Imaging experiments and b) as an Innovative research core to develop new Imaging protocols and agents for high priority targets derived from different projects. The Projects will use the Core not only to detect the location and size of tumors, but importantly also to monitor responses to drugs that target specific pathways. For example, activation of the K-Ras and PI3K pathways turns on genes for glucose uptake and metabolism; drugs that turn off these pathways often cause acute changes in 18FDG-PET, prior to tumor shrinkage. Likewise, Myc regulates genes for glucose uptake so drugs that affect the Myc pathway are also expected to have acute effects on glucose uptake and metabolism. The Core efficiently leverages existing imaging resources but focuses specifically on unique aspects of PDAC biology and therapeutic interventions proposed in the Projects. Specifically the core will provide: a) all routine imaging technologies and protocols for PDAC imaging in GEMS, b) techniques and imaging protocols that are clinically translatable including MRI and PET-CT, c) high throughput optical screening capabilities, d) technical expertise for quantitative image analysis, e) the necessary infrastructure and expertise for image archival and distribution throughout the consortium, f) expertise in the design, synthesis and validation of novel imaging probes relevant to the goals of the projects and g) physiologic support and logistics for longitudinal Imaging in cohorts of mice including housing. The core is supported by a substantial infrastructure in the Center for Systems Biology at MGH, which includes a broad biological chemistry effort, computation and quantitative Image analysis, as well as a web-based bioinformatics platform (MlPortal) to assure access to imaging studies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Bioorthogonal probe development for highly parallel in vivo imaging
-
批准号:10596786
-
项目类别:
-
资助金额:$41.58万
-
财政年份:2023
-
负责人:RALPH WEISSLEDER, MD, PHD
-
依托单位:
Temporal analysis of the GBM tumor microenvironment during myeloid cell activating therapy
-
批准号:10704328
-
项目类别:
-
资助金额:$57.73万
-
财政年份:2023
-
负责人:RALPH WEISSLEDER, MD, PHD
-
依托单位:
Ultrasenstive vesicle analysis in precancerous pancreatic neoplasm (IPMN)
-
批准号:10615899
-
项目类别:
-
资助金额:$37.66万
-
财政年份:2020
-
负责人:RALPH WEISSLEDER, MD, PHD
-
依托单位:
Ultrasenstive vesicle analysis in precancerous pancreatic neoplasm (IPMN)
-
批准号:10403494
-
项目类别:
-
资助金额:$37.66万
-
财政年份:2020
-
负责人:RALPH WEISSLEDER, MD, PHD
-
依托单位:
Single Circulating Vesicle Analysis for Early Cancer Detection
-
批准号:9913496
-
项目类别:
-
资助金额:$21.92万
-
财政年份:2019
-
负责人:RALPH WEISSLEDER, MD, PHD
-
依托单位:
Imaging of nanotherapeutic drug action
-
批准号:9261150
-
项目类别:
-
资助金额:$58.57万
-
财政年份:2017
-
负责人:RALPH WEISSLEDER, MD, PHD
-
依托单位:
Multiplexed analysis of exosomes in cancer nano therapy
-
批准号:9078198
-
项目类别:
-
资助金额:$39.12万
-
财政年份:2016
-
负责人:RALPH WEISSLEDER, MD, PHD
-
依托单位:
Multiplexed analysis of exosomes in cancer nano therapy
-
批准号:9487955
-
项目类别:
-
资助金额:$38.9万
-
财政年份:2016
-
负责人:RALPH WEISSLEDER, MD, PHD
-
依托单位:
Analysis of scant cancer cells in fine needle aspirates
-
批准号:9023623
-
项目类别:
-
资助金额:$43.33万
-
财政年份:2016
-
负责人:RALPH WEISSLEDER, MD, PHD
-
依托单位:
Analysis of scant cancer cells in fine needle aspirates
-
批准号:9324962
-
项目类别:
-
资助金额:$43.33万
-
财政年份:2016
-
负责人:RALPH WEISSLEDER, MD, PHD
-
依托单位:
Single Cell Imaging of the Heart
-
批准号:9265709
-
项目类别:
-
资助金额:$43.45万
-
财政年份:2014
-
负责人:RALPH WEISSLEDER, MD, PHD
-
依托单位:
Single Cell Imaging of the Heart
-
批准号:9049540
-
项目类别:
-
资助金额:$43.45万
-
财政年份:2014
-
负责人:RALPH WEISSLEDER, MD, PHD
-
依托单位:
Single Cell Imaging of the Heart
-
批准号:8667532
-
项目类别:
-
资助金额:$43.45万
-
财政年份:2014
-
负责人:RALPH WEISSLEDER, MD, PHD
-
依托单位:
Single Cell Imaging of the Heart
-
批准号:8843950
-
项目类别:
-
资助金额:$42.8万
-
财政年份:2014
-
负责人:RALPH WEISSLEDER, MD, PHD
-
依托单位:
Whole Genome Amplification and Sequencing of Single Cancer Cells
-
批准号:8624939
-
项目类别:
-
资助金额:$43.69万
-
财政年份:2013
-
负责人:RALPH WEISSLEDER, MD, PHD
-
依托单位:
Whole Genome Amplification and Sequencing of Single Cancer Cells
-
批准号:8740473
-
项目类别:
-
资助金额:$40.69万
-
财政年份:2013
-
负责人:RALPH WEISSLEDER, MD, PHD
-
依托单位:
Whole Genome Amplification and Sequencing of Single Cancer Cells
-
批准号:8909080
-
项目类别:
-
资助金额:$41.95万
-
财政年份:2013
-
负责人:RALPH WEISSLEDER, MD, PHD
-
依托单位:
Quantitative analysis of pharmacological mechanism by intravital imaging
-
批准号:8902052
-
项目类别:
-
资助金额:$80.86万
-
财政年份:2011
-
负责人:RALPH WEISSLEDER, MD, PHD
-
依托单位:
Quantitative analysis of pharmacological mechanism by intravital imaging
-
批准号:8703640
-
项目类别:
-
资助金额:$78.43万
-
财政年份:2011
-
负责人:RALPH WEISSLEDER, MD, PHD
-
依托单位:
Quantitative analysis of pharmacological mechanism by intravital imaging
-
批准号:8336819
-
项目类别:
-
资助金额:$80.79万
-
财政年份:2011
-
负责人:RALPH WEISSLEDER, MD, PHD
-
依托单位:
海外基金